The suppliers of the Mantoux in Europe are decreasing. Novartis has announced that it will stop supplying in Italy in a few months. Chiron stopped supplying the UK about 3 years ago. This leaves SSI as almost the only provider for Europe.
There must be a reason for this.
Also, as the market is left to SSI clinicians take the opportunity of the change to look for another methodology, again accelerating the move to IGRAs.
Alex
unseating the mantoux?, page-3
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
